[{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/","commit":"9cbd69eefa","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fourth batch of thirty approved products","file":"src/data/spikes/cholangiocarcinoma.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pemigatinib\" }]"}]},{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/cholangiocarcinoma.ts","type":"changed","fields":[{"field":"tldr","before":"\"The first targeted therapy for bile duct cancer, for tumours with an FGFR2 gene fusion.\"","after":"\"Pemigatinib was the first targeted therapy for bile duct cancer, for tumours with an FGFR2 gene fusion.\""}]},{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/","commit":"06899fbdf4","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: hepatocellular carcinoma, biliary tract cancer, neuroendocrine tumours (deep, with structured outcomes, dosing, toxicity, regulatory","file":"src/data/spikes/cholangiocarcinoma.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"},{"field":"terms"}]}]